Skip to main content

Prosthetic Joint Infections of Hip

4
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Trellis Bioscience
Trellis BioscienceCA - Redwood City
1 program
1
TRL1068Phase 21 trial
Active Trials
NCT06621251Recruiting60Est. Nov 2026
Qeen Biotechnologies
2 programs
2
Five phage anti-Staphylococcus aureus bacteriophage cocktailPhase 1/21 trial
phage therapyPhase 1/21 trial
Active Trials
NCT07461337Not Yet Recruiting1Est. Mar 2027
NCT06814756Active Not Recruiting1Est. Mar 2026
Precisio Biotix Therapeutics
1 program
1
Phage therapyPhase 1/21 trial
Active Trials
NCT06456424Active Not Recruiting1Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Trellis BioscienceTRL1068
Qeen BiotechnologiesFive phage anti-Staphylococcus aureus bacteriophage cocktail
Qeen Biotechnologiesphage therapy
Precisio Biotix TherapeuticsPhage therapy

Clinical Trials (4)

Total enrollment: 63 patients across 4 trials

NCT06621251Trellis BioscienceTRL1068

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

Start: Apr 2025Est. completion: Nov 202660 patients
Phase 2Recruiting
NCT07461337Qeen BiotechnologiesFive phage anti-Staphylococcus aureus bacteriophage cocktail

Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection

Start: Mar 2026Est. completion: Mar 20271 patients
Phase 1/2Not Yet Recruiting
NCT06814756Qeen Biotechnologiesphage therapy

Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection

Start: Mar 2025Est. completion: Mar 20261 patients
Phase 1/2Active Not Recruiting
NCT06456424Precisio Biotix TherapeuticsPhage therapy

Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection

Start: Nov 2024Est. completion: Nov 20251 patients
Phase 1/2Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 63 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.